Literature DB >> 21145860

Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.

Adam J Gehring1, Shao-An Xue, Zi Zong Ho, Denise Teoh, Christiane Ruedl, Adeline Chia, Sarene Koh, Seng Gee Lim, Mala K Maini, Hans Stauss, Antonio Bertoletti.   

Abstract

BACKGROUND & AIMS: Virus-specific T cells capable of controlling HBV and eliminating hepatocellular carcinoma (HCC) expressing HBV antigens are deleted or dysfunctional in patients with chronic HBV or HBV-related HCC. The goal of this study was to determine if T cell receptor (TCR) gene transfer can reconstitute HBV-specific T cell immunity in lymphocytes of chronic HBV patients and investigate whether HCC cells with natural HBV-DNA integration can be recognized by genetically modified T cells.
METHODS: We used vector-mediated gene transfer to introduce HLA-A2-restricted, HBV-specific TCRs into T cells of chronic HBV as well as HBV-related HCC patients.
RESULTS: The introduced TCRs were expressed on the cell surface, evidenced by Vβ and pentamer staining. TCR transduced T cells produced IFN-γ, TNF-α, IL-2, and lysed HBV infected hepatocyte-like cell lines. Furthermore, HCC cell lines with natural HBV-DNA integration could be recognized by HBV-specific TCR-re-directed T cells.
CONCLUSIONS: TCR re-directed HBV-specific T cells generated from PBMC of chronic HBV and HBV-related HCC patients were multifunctional and capable of recognizing HBV-infected cells and HCC tumor cells expressing viral antigens from naturally integrated HBV DNA. These genetically modified T cells could be used to reconstitute virus-specific T cell immunity in chronic HBV patients and target tumors in HBV-related HCC.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21145860     DOI: 10.1016/j.jhep.2010.10.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  85 in total

1.  Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.

Authors:  Katja Mueller; Anne von Mässenhausen; Ulrike Aichele; Lilian Stärck; Matthias Leisegang; Wolfgang Uckert; Hanspeter Pircher
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

2.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

3.  A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.

Authors:  Andrea Pavesi; Anthony T Tan; Sarene Koh; Adeline Chia; Marta Colombo; Emanuele Antonecchia; Carlo Miccolis; Erica Ceccarello; Giulia Adriani; Manuela T Raimondi; Roger D Kamm; Antonio Bertoletti
Journal:  JCI Insight       Date:  2017-06-15

4.  Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Authors:  Hsueh-Ling Janice Oh; Adeline Chia; Cynthia Xin Lei Chang; Hoe Nam Leong; Khoon Lin Ling; Gijsbert M Grotenbreg; Adam J Gehring; Yee Joo Tan; Antonio Bertoletti
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

5.  Stability screening of arrays of major histocompatibility complexes on combinatorially encoded flow cytometry beads.

Authors:  Shi Ling Chew; Ming Yan Or; Cynthia Xin Lei Chang; Adam J Gehring; Antonio Bertoletti; Gijsbert M Grotenbreg
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

6.  Immunotherapy: Therapeutic potential of genetically modified HBV-specific T cells for chronic HBV infection and HBV-related HCC.

Authors:  Natalie J Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

7.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 8.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

9.  Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro.

Authors:  Alexander Hoh; Maximilian Heeg; Yi Ni; Anita Schuch; Benedikt Binder; Nadine Hennecke; Hubert E Blum; Michael Nassal; Ulrike Protzer; Maike Hofmann; Stephan Urban; Robert Thimme
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

10.  Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.

Authors:  Longhao Sun; Hao Guo; Ruoyu Jiang; Li Lu; Tong Liu; Xianghui He
Journal:  Tumour Biol       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.